Composition and use thereof
By combining Poria cocos extract with vitamin B, the absorption efficiency of vitamin B is improved, solving the problems of low absorption efficiency and high-dose side effects of vitamin B supplements, and achieving high-efficiency absorption and enhanced metabolic function.
Patent Information
- Application Number
- PCT/CN2026/096902
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing vitamin B supplements have limited absorption mechanisms, resulting in low absorption efficiency for some people. Furthermore, high doses of supplements may cause side effects such as gastrointestinal discomfort and skin flushing.
A combination of Poria cocos extract and vitamin B is used, wherein the weight ratio of Poria cocos extract to vitamin B is 1:0.1-5. By using Poria cocos extract and vitamin B together, the absorption efficiency of vitamin B is improved, and the side effects of high doses of vitamin B are avoided.
It improves the absorption efficiency of vitamin B, enhances the body's metabolic function, improves the mitochondrial respiration capacity of cells, reduces intracellular glycolysis, and increases the cellular glycolysis reserve, thereby achieving the purpose of rapid energy replenishment and enhanced vitality.
Smart Images

Figure CN2026096902_19112026_PF_FP_ABST
Abstract
Description
Compositions and their uses Technical Field
[0001] This invention relates to a composition and its use, and more particularly, to a composition and its use that improves the absorption efficiency of vitamin B. Background Technology
[0002] The B vitamins are a collective term for various water-soluble vitamins, including B1 (thiamine), B2 (riboflavin), B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folic acid), and B12 (hydrocobalamin). They play crucial roles in human metabolism, particularly in energy production, amino acid metabolism, red blood cell formation, and the normal functioning of the nervous system. Because these vitamins cannot be stored in large quantities in the body, they must be continuously obtained through daily diet or supplements to maintain their physiological functions.
[0003] However, due to the limited absorption mechanisms of some vitamin B supplements, certain groups may experience low absorption efficiency of vitamin B. While some high-dose vitamin B supplements can compensate for the aforementioned low absorption efficiency, they may cause side effects such as gastrointestinal discomfort and skin flushing.
[0004] Given that existing vitamin B supplements often require high doses to compensate for their insufficient bioavailability, but high doses of vitamin B supplements may cause side effects such as gastrointestinal discomfort and skin flushing in some users, there is a desire to find a new formula that can enhance the absorption efficiency of vitamin B supplements, so that vitamin B supplements can still effectively exert their effects under low dose conditions. Summary of the Invention
[0005] In view of the above needs, the present invention provides a composition and its use, which, by combining Poria cocos extract with vitamin B, not only improves the absorption efficiency of vitamin B, but also avoids the side effects caused by taking high doses of vitamin B to provide the body with the required vitamin B, and also has the benefit of maintaining normal energy metabolism, so as to achieve the purpose of rapid energy replenishment and enhanced vitality.
[0006] Therefore, an object of the present invention is to provide a composition comprising Poria cocos extract and vitamin B, wherein the weight ratio of the Poria cocos extract to the vitamin B is Poria cocos extract: vitamin B = 1:0.1-5, preferably 1:0.1-2.
[0007] In another embodiment of the composition of the present invention, the Poria cocos extract is a polar solvent extract of Poria cocos.
[0008] In another embodiment of the composition of the present invention, the vitamin B is selected from the group consisting of: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B9, vitamin B12, and combinations thereof. In this embodiment, vitamin B1 is preferred.
[0009] In the above embodiments of the composition of the present invention, the composition is a pharmaceutical composition, a food composition, a cosmetic composition, a skincare composition, or a feed composition. Wherein, when the composition is a pharmaceutical composition or a food composition, its dosage is such that the total daily dose of vitamin B is 2.5 mg to 50 mg, preferably 2.5 mg to 20 mg.
[0010] Another object of the present invention is to provide a use of the composition described above in the preparation of a pharmaceutical composition, wherein the pharmaceutical composition is used for at least one of the following: improving endurance performance, improving athletic ability, enhancing or restoring physical strength, promoting fatigue relief, preventing or improving myocardial weakness, improving cardiac function, maintaining normal energy metabolism, and maintaining or improving nervous system function.
[0011] To make the above-mentioned objectives, technical features and advantages of the present invention more apparent and understandable, the following detailed description is provided with reference to some specific embodiments. Attached Figure Description
[0012] Figure 1 shows photographs of the normal morphology and the morphology of C2C12 myoblasts 6 days after differentiation.
[0013] Figure 2 shows the effect of different concentrations of TNF-α on the cell survival rate of C2C12 myoblasts;
[0014] Figure 3 shows the effect of different concentrations of TNF-α on the mitochondrial membrane potential of C2C12 myoblasts;
[0015] Figure 4 shows the effect of different concentrations of TNF-α on the level of reactive oxygen species in C2C12 myoblasts;
[0016] Figure 5 shows the effect of different concentrations of Poria cocos extract on the cell survival rate of C2C12 myoblasts.
[0017] Figure 6 shows the effect of different concentrations of vitamin B on the cell survival rate of C2C12 myoblasts;
[0018] Figure 7 shows the effect of different concentrations of Poria cocos extract on cell survival in a C2C12 cell fatigue model.
[0019] Figure 8 shows the effect of different concentrations of Poria cocos extract on reactive oxygen species levels in a C2C12 cell fatigue model.
[0020] Figure 9 shows the effect of different concentrations of Poria cocos extract on mitochondrial membrane potential in a C2C12 cell fatigue model.
[0021] Figure 10 shows the effect of different ratios of Poria cocos extract to vitamin B on cell survival in a C2C12 cell fatigue model.
[0022] Figure 11 shows the effect of different ratios of Poria cocos extract to vitamin B on reactive oxygen species levels in a C2C12 cell fatigue model.
[0023] Figure 12 shows the effect of different ratios of Poria cocos extract and vitamin B on the mitochondrial membrane potential of a C2C12 cell fatigue model.
[0024] Figure 13 shows the process of each stage of the oxygen consumption rate experiment.
[0025] Figure 14 shows the effect of different ratios of Poria cocos extract to vitamin B on the basal respiratory oxygen consumption rate of a C2C12 cell fatigue model.
[0026] Figure 15 shows the effect of different ratios of Poria cocos extract to vitamin B on the maximum respiratory oxygen consumption rate of a C2C12 cell fatigue model.
[0027] Figure 16 shows the effect of different ratios of Poria cocos extract to vitamin B on the proton leakage oxygen consumption rate in a C2C12 cell fatigue model.
[0028] Figure 17 shows the effect of different ratios of Poria cocos extract and vitamin B on the oxygen consumption rate of ATP production in a C2C12 cell fatigue model.
[0029] Figure 18 shows the effect of different ratios of Poria cocos extract and vitamin B on the oxygen consumption rate of the standby respiratory capacity in a C2C12 cell fatigue model.
[0030] Figure 19 shows the process of each stage of the extracellular acidification rate experiment.
[0031] Figure 20 shows the effect of different ratios of Poria cocos extract to vitamin B on the increase rate of extracellular acidification reflecting glycolysis in a C2C12 cell fatigue model.
[0032] Figure 21 shows the effect of different ratios of Poria cocos extract to vitamin B on the increase rate of extracellular acidification reflecting maximum glycolysis in a C2C12 cell fatigue model.
[0033] Figure 22 shows the effect of different ratios of Poria cocos extract to vitamin B on the increase rate of extracellular acidification of glycolytic reserve in a C2C12 cell fatigue model. Detailed Implementation
[0034] The following describes some specific embodiments of the present invention; however, the present invention can be practiced in many different forms and the scope of protection of the present invention should not be limited to the specific embodiments described.
[0035] Furthermore, unless otherwise stated herein, the terms “a,” “the,” and similar terms used in this specification (especially in the following description of the techniques and preferred embodiments, which will be presented below to enable those skilled in the art to understand the features of the invention; however, the invention may be practiced in many different forms without departing from its spirit, and the scope of protection of the invention should not be construed as limited to the scope of the claims set forth in this specification) should be understood to include both singular and plural forms; “effective amount” refers to the amount of compound that, when administered to an individual, can effectively at least partially improve the individual’s condition; the unit “mg / kg body weight” refers to the amount required per kilogram of body weight per individual.
[0036] In this specification, "individual" refers to a human or non-human mammal; "treatment" includes preventing a specific disease or symptom, alleviating a specific disease or symptom, and / or preventing or eliminating the condition; "prevention" refers to suppressing or preventing the onset of a specific condition, maintaining good health in a susceptible individual, or establishing tolerance to the disease in that individual; "treatment" should not be interpreted as treating an individual until complete recovery, but should include maintaining the progression of the disease or symptoms in an individual at a substantially static level, increasing the rate of recovery in an individual, reducing the severity of a specific condition, or improving the quality of life of a patient. "Pharmaceutically acceptable salt" refers to a salt that, when administered to an organism, produces the same or similar pharmacological activity as the parent compound and is physiologically tolerable (i.e., has the least possible toxicity).
[0037] In this specification, the “weight ratio” of the components in the composition is expressed on a dry weight basis.
[0038] In this specification, the numerical ranges used (e.g., 5 to 100) should be understood to include all rational numbers within that range and any range of rational numbers within that range. Therefore, the numerical ranges used in this specification include all possible combinations of values between the listed minimum and maximum values. Furthermore, when the word "about" is used before a numerical value, it substantially means a difference of less than 10%, preferably less than 5%, from the stated value.
[0039] The advantages of the composition of the present invention compared to the prior art lie in improving the absorption efficiency of vitamin B by combining Poria cocos extract with vitamin B, thereby avoiding the side effects caused by taking high doses of vitamin B to provide the body with the required vitamin B concentration, while also maintaining normal energy metabolism, achieving the purpose of rapid energy replenishment and enhanced vitality. The following provides a detailed description of the embodiments of the composition of the present invention.
[0040] The composition of the present invention comprises Poria cocos extract and vitamin B. When the weight ratio of Poria cocos extract to vitamin B is 1:0.1-5, preferably 1:0.1-2, it can effectively improve the absorption efficiency of vitamin B and further enhance the body's metabolic function, including improving mitochondrial respiration, reducing intracellular glycolysis, increasing cellular glycolysis reserves, and improving cellular fatigue. The composition of the present invention can be used to prepare a pharmaceutical composition, which, based on the aforementioned efficacy of maintaining normal energy metabolism, can be further applied to at least one of the following: improving endurance performance, improving athletic ability, enhancing or restoring physical strength, promoting fatigue elimination, preventing or improving myocardial weakness, improving cardiac function, maintaining normal energy metabolism, and maintaining or improving nervous system function.
[0041] In the compositions of the present invention, the weight ratio of Poria cocos extract to vitamin B can be, for example, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2.0, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:1. :2.6, 1:2.7, 1:2.8, 1:2.9, 1:3.0, 1:3.1, 1:3.2, 1:3.3, 1:3.4, 1:3.5, 1:3.6, 1:3.7, 1:3.8, 1:3.9, 1:4.0, 1:4.1, 1:4.2, 1:4.3, 1:4.4, 1:4.5, 1:4.6, 1:4.7, 1:4.8, 1:4.9, 1:5.0, or any of the aforementioned weight ratios, such as 1:2.5 to 1:3.5.
[0042] In the composition of the present invention, the vitamin B contained may be one vitamin B or multiple vitamin B, and is preferably selected from the group consisting of: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B9, vitamin B12 and combinations thereof, and more preferably vitamin B1.
[0043] Poria cocos (Schw.) Wolf is a medicinal material containing dried sclerotia of the fungus Poria cocos (Schw.) Wolf. This fungus often parasitizes pine roots, with a light brown or dark brown outer skin (the pericarp of Poria cocos) and a pink or white interior (the flesh of Poria cocos).
[0044] According to the present invention, the Poria cocos extract used can be an extract obtained by extracting Poria cocos raw material using a polar solvent. The Poria cocos raw material can be the flesh, peel, and / or fermentation product of Poria cocos; the polar solvent can be water and / or C1-C4 alcohols, and preferably water, ethanol, or a combination thereof. The amount of polar solvent used to provide the Poria cocos extract required by the present invention is not particularly limited, as long as it can uniformly disperse the raw material. In a specific embodiment of the present invention, ethanol is used as the polar solvent, and the raw material is dispersed in ethanol at a volume ratio of approximately 1:8 for extraction.
[0045] In the above extraction operation, the extraction is carried out for a period of time to achieve the desired degree of extraction. Taking ethanol as the polar solvent as an example, the extraction is usually carried out for at least 1 hour, preferably at least 2 hours, and more preferably at least 3 hours. Other operations such as boiling, cooling, filtration, vacuum concentration, and resin column chromatography may be added as needed.
[0046] If necessary, the extract obtained by extracting Poria cocos raw material using a polar solvent can be sequentially alkalized and acidified. "Alkalization" refers to using any suitable alkaline substance to increase the pH value of the material (in this invention, the extract obtained by extracting Poria cocos raw material using a polar solvent). In one specific embodiment of the invention, sodium hydroxide is used to carry out this alkalization reaction.
[0047] Generally, the pH value of the material is raised to not less than about 10 during the alkalization step; preferably to not less than about 11; and most preferably to not less than about 12. In one specific embodiment of the invention, 1N sodium hydroxide is added during the alkalization step to raise the pH value of the extract to about 12. After raising the pH value of the extract, the alkalization reaction is carried out at a higher temperature as needed. For example, the alkalization reaction is carried out at a temperature not less than 50°C, preferably not less than 60°C. As shown in the accompanying examples, the alkalization reaction can be carried out at a temperature of, for example, about 70°C.
[0048] The term "acidification" refers to the use of any suitable acidic substance to lower the pH value of the material (in this invention, the aforementioned alkalized extract). In one specific embodiment of the invention, hydrochloric acid is used to lower the pH value of the alkalized extract.
[0049] Generally, there are no special requirements regarding the degree of pH reduction achieved by the acidification treatment; as long as the pH value is lowered, it is acceptable. For example, the pH value of the extract should be lowered by at least about 3.0, preferably by at least about 4.0. In one specific embodiment of the invention, the pH value of the alkalized extract is lowered to about 7 during the acidification treatment.
[0050] The Poria cocos extract used according to the present invention can also be a dried product, which can be provided by drying the extract obtained above, or without alkalization and acidification treatment. To achieve the maximum extraction efficiency, the Poria cocos raw material can be repeatedly extracted with the same or different polarity solvents as needed, and the extracts obtained from these multiple extractions can be combined and then dried, or alkalized and acidified as needed. Each extraction operation can be carried out with the same or different polarity solvents.
[0051] In a preferred embodiment of the composition of the present invention, one or more other active ingredients may be included as needed, or the composition may be used in combination with a drug or food containing one or more other active ingredients, to further enhance the efficacy of the composition or increase the flexibility and compatibility of the formulation, as long as the other active ingredients do not have an adverse effect on the efficacy of the composition of the present invention.
[0052] The compositions provided according to the present invention can be pharmaceutical compositions, food compositions, cosmetic compositions, skincare compositions, or feed compositions. The pharmaceutical compositions may be in any suitable form without particular limitation, depending on the desired application and the appropriate dosage form.
[0053] For example, but not limited to, the pharmaceutical composition can be administered to individuals in need via oral or non-oral routes (e.g., transdermal, subcutaneous, or intravenous injection). Depending on the form of use and intended application, a suitable carrier may be selected to provide the pharmaceutical composition, including excipients, diluents, adjuvants, stabilizers, absorption delayers, disintegrants, solubilizers, emulsifiers, antioxidants, binders, binders, thickeners, dispersants, suspending agents, lubricants, and hygroscopic agents.
[0054] Taking a dosage form suitable for oral administration as an example, the pharmaceutical composition provided according to the present invention may contain any pharmaceutically acceptable carrier that will not adversely affect the desired efficacy of the Poria cocos extract and vitamin B of the present invention, such as: water, saline, glucose, glycerol, ethanol or analogues thereof, cellulose, starch, sugar bentonite, and combinations thereof. The pharmaceutical composition may be provided in a dosage form suitable for oral administration using any suitable method, such as: tablets (e.g., sugar-coated tablets), pills, capsules, granules, powders, fluid extracts, solutions, syrups, suspensions, tinctures, etc.
[0055] Taking dosage forms suitable for transdermal administration as an example, the pharmaceutical compositions provided according to the present invention may be in the form of patches, emulsions, creams, gels (e.g., hydrogels), pastes (e.g., dispersants, ointments), sprays, or solutions (e.g., suspensions) for direct external use, but are not limited thereto.
[0056] As for injections or infusions suitable for subcutaneous or intravenous injection, the pharmaceutical composition provided according to the present invention may contain one or more components such as isotropic solutions, salt buffers (e.g., phosphate buffer or citrate buffer), solubilizers, emulsifiers, 5% sugar solutions, and other carriers, and may be provided in dosage forms such as intravenous infusions, emulsion intravenous infusions, dry powder injections, suspension injections, or dry powder suspension injections. Alternatively, the pharmaceutical composition may be prepared as a pre-injection solid, provided in a dosage form soluble in other solutions or suspensions, or in an emulsifiable dosage form, and the pre-injection solid may be dissolved in other solutions or suspensions or emulsified before being administered to the individual in need, to provide the desired injection.
[0057] The pharmaceutical composition provided by the present invention can be administered at different frequencies, such as once a day, multiple times a day, or once every few days, depending on the individual's needs, age, weight, and health condition. The content ratio of Poria cocos extract and vitamin B in the pharmaceutical composition provided by the present invention can be adjusted according to actual application requirements.
[0058] When the composition of the present invention is a pharmaceutical composition or a food composition, the dosage is such that the total daily dose of vitamin B is 2.5 mg to 50 mg, preferably 2.5 mg to 20 mg, for example, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 32.5 mg, 35 mg, 37.5 mg, 40 mg, 42.5 mg, 45 mg, 47.5 mg, 50 mg, or any two of the aforementioned values in parts, for example, 2.5 mg to 25 mg.
[0059] As needed, the pharmaceutical composition, food composition, cosmetic composition, skincare composition, or feed composition provided according to the present invention may contain appropriate amounts of additives, such as flavoring agents, coloring agents, coloring agents, etc., which can improve the taste and visual appeal of the pharmaceutical composition, food composition, cosmetic composition, skincare composition, or feed composition when consumed, as well as buffering agents, preservatives, antiseptics, antibacterial agents, antifungal agents, etc., which can improve the stability and storability of the pharmaceutical composition, food composition, cosmetic composition, skincare composition, or feed composition.
[0060] The food composition provided by the present invention can be a health food, a health care food, a functional food, a nutritional supplement, or a special nutritional food, and can be made into products such as dairy products, processed meat products, bread, pasta products, biscuits, lozenges, capsules, fruit juices, teas, sports drinks, nutritional drinks, soups, powders, jellies, gummies, solid-liquid mixtures, or solid-liquid mixtures, but is not limited thereto.
[0061] The health foods, health supplements, functional foods, nutritional supplements, and special nutritional foods provided by this invention can be consumed at different frequencies, such as once a day, multiple times a day, or once every few days, depending on the individual's age, weight, and health condition. The content of Poria cocos extract and vitamin B in the health foods, health supplements, functional foods, nutritional supplements, and special nutritional foods provided by this invention can also be adjusted for specific groups, preferably to the recommended daily intake. As mentioned above, the daily intake is such that the total daily dose of vitamin B is 2.5 mg to 50 mg, preferably 2.5 mg to 20 mg.
[0062] The recommended dosage, usage standards and conditions for specific groups (such as athletes, heart patients, diabetic patients, pregnant women, the elderly, sarcopenia patients, etc.), or suggestions for taking with other foods or medicines can be indicated on the outer packaging of the health foods, health care foods, functional foods, nutritional supplements and / or special nutritional foods provided by this invention, so that users can take them at home without safety concerns without the guidance of a doctor, pharmacist or relevant personnel.
[0063] The cosmetic or skincare composition provided by the present invention may be in any suitable form without particular limitation. For example, the cosmetic or skincare composition may be in the form of a lotion, cream, gel (e.g., hydrogel), or solution (e.g., serum, lotion) for direct external use, but is not limited thereto. The cosmetic or skincare composition provided by the present invention may contain different amounts of Poria cocos extract and vitamin B, depending on the product form.
[0064] The feed composition provided according to the present invention may contain any other edible raw materials that will not adversely affect the desired benefits of the Poria cocos extract and vitamin B, such as emulsifiers, skim milk powder, soy protein, sugars, starch, processed starch, dextrin, and salts such as inorganic or organic salts. The feed composition may be provided in solid, liquid, or emulsified form using any suitable method. The content of Poria cocos extract and vitamin B in the feed composition provided according to the present invention may vary depending on the product form.
[0065] This invention also provides a method for improving endurance performance, enhancing athletic ability, strengthening or restoring physical strength, promoting fatigue relief, preventing or improving myocardial weakness, improving cardiac function, maintaining normal energy metabolism, or maintaining or improving nervous system function, comprising administering an effective amount of a composition to an individual in need, wherein the composition comprises Poria cocos extract and vitamin B. The formulation, route of administration, form of administration, frequency of administration, and related applications of this composition are as described above.
[0066] The present invention will now be further illustrated by the following embodiments. These embodiments are provided for illustrative purposes only and are not intended to limit the scope of protection of the invention. The scope of protection of the present invention is as shown in the appended claims.
[0067] Preparation Example 1: Preparation of Poria cocos extract
[0068] 700 kg of Poria cocos (originating from Yunnan Province, China) was soaked in 75% ethanol at a volume ratio of approximately 1:8 (Poria cocos: 75% ethanol) at room temperature for 12 hours, followed by boiling and extraction (for 3 hours). This extraction process was repeated three times. The extracts from the three extractions were combined and filtered to remove insoluble matter. Next, the extract was concentrated under reduced pressure to remove ethanol, and then dried using a spray dryer to obtain a monoethanol extract.
[0069] Take 3250 g of the aforementioned ethanol extract and disperse it uniformly in pure water at a volume ratio of approximately 1:10 (extract: pure water). Next, add sodium hydroxide to bring the alkalinity of the mixture to 1N (i.e., raise the pH of the mixture to approximately 12), then pour it into a mixing tank maintained at 70°C and stir evenly until the reaction is complete. Then, neutralize with 12N concentrated hydrochloric acid to lower the pH of the mixture to 7, and centrifuge at 1000 rpm (using a plate centrifuge) at room temperature for 30 minutes. Remove the filtrate and wash the remaining insoluble matter with pure water. Dry the insoluble matter and grind it into powder. Extract with 95% ethanol at a volume ratio of approximately 1:40 (insoluble matter: 95% ethanol). Repeat this extraction step three times. Combine the extracts from the three extractions and concentrate under reduced pressure to remove the ethanol, obtaining 2000 g of product (this is the Poria cocos extract used in subsequent experiments).
[0070] Preparation Example 2: Establishment of a TNF-α-induced C2C12 myoblast fatigue model
[0071] (2-1) Differentiation of C2C12 myoblasts
[0072] C2C12 cells (i.e., mouse myocytes, purchased from ATCC) were cultured in H-DMEM medium (purchased from Sigma-Aldrich) containing 10% fetal bovine serum (purchased from Ingelheim). Once the C2C12 cells reached 90% confluence (i.e., a mixed monolayer of cells covering 90% of the surface area), the medium was replaced with differentiation-inducing medium containing 2% horse serum. The culture results are shown in Figure 1. Undifferentiated C2C12 cells exhibited a fibroblast-like morphology with mononuclear, spindle-shaped, or star-shaped structures (see top row of Figure 1), and were loosely arranged. After differentiation began, C2C12 cells ceased proliferation, gradually elongated, and established connections with neighboring cells, forming short myotubes containing several nuclei. Subsequently, the myotubes further elongated and thickened, with the internal myofibrils becoming more orderly, eventually developing into long, thick, mature myotubes containing numerous nuclei (see bottom row of Figure 1). The entire differentiation process took approximately 6 days.
[0073] (2-2) TNF-α-induced fatigue of C2C12 myoblasts
[0074] C2C12 myoblasts were seeded in 96-well plates, with each well containing approximately 1.2 x 10⁴ cells. Seven groups of samples were seeded, with three wells per group. These seven groups were then treated for six days with differentiation medium containing different final concentrations of TNF-α (0, 5, 10, 20, 30, 40, and 50 ng / mL). After treatment, cell viability was assessed using the MTT assay. The levels of reactive oxygen species (ROS, induced by TNF-α and reflecting the degree of mitochondrial dysfunction) and mitochondrial membrane potential (MMP, a core indicator of mitochondrial energy production and reflecting mitochondrial health) were measured using a Seahorse XF24 cellular energy metabolism analyzer to screen the TNF-α concentration for subsequent experiments. An increase in ROS and a decrease in MMP indicate cellular fatigue.
[0075] The experimental results are shown in Table 1 and Figures 2 to 4. When the TNF-α concentration was 10 ng / mL, the ROS level increased significantly (P<0.05 compared with 0 ng / mL TNF-α, indicated by *). When the concentration reached 20 ng / mL, cell viability and MMP both decreased significantly, while the ROS level increased significantly (P<0.01 compared with 0 ng / mL TNF-α, indicated by **). When the TNF-α concentration was ≥30 ng / mL, cell viability decreased significantly. To observe obvious signs of cell fatigue in the experiment while still ensuring a sufficient number of cells survive for subsequent experiments, 20 ng / mL of TNF-α was chosen as the concentration for subsequent experiments.
[0076] Table 1
[0077] Example 1: Effects of different concentrations of Poria cocos extract and vitamin B on cell survival in a TNF-α-induced C2C12 cell fatigue model
[0078] To investigate the effect of Poria cocos extract on cell viability in a C2C12 cell fatigue model, the following experimental procedures were followed. C2C12 myoblasts were seeded in 96-well plates according to the steps in Preparation Example 2 (2-2), with three wells per group, for a total of 10 groups. These 10 groups were treated for 6 days with differentiation medium containing different final concentrations of Poria cocos extract (0, 0.01, 0.1, 0.25, 0.5, 0.8, 1.0, 1.4, 1.8, and 2.0 mg / mL, calculated based on the final concentration of the dried Poria cocos extract powder added to the differentiation medium). After treatment, cell viability in each group was assessed using the MTT assay.
[0079] The experiment involving Poria cocos extract was repeated, but vitamin B1 was used instead of the dried powder of Poria cocos extract to observe the effect of vitamin B on cell survival rate in a C2C12 cell fatigue model.
[0080] The experimental results are shown in Table 2, Figure 5, and Figure 6 below. The results show that in order to maintain a better C2C12 cell survival rate, the concentration of Poria cocos extract should be controlled between 0.01 and 0.8 mg / mL, and the concentration of vitamin B should be controlled between 0.01 and 1.0 mg / mL. Therefore, subsequent experiments on TNF-α-induced C2C12 cells were conducted within these concentration ranges.
[0081] Table 2
[0082] Example 2: Testing the effective concentration of Poria cocos extract in a TNF-α-induced C2C12 cell fatigue model
[0083] Following the steps in Preparation Example 2 (2-2), C2C12 myoblasts were seeded in 96-well plates, with three wells per group, for a total of 7 groups: NC group, MD group, 0.05 group, 0.1 group, 0.2 group, 0.4 group, and 0.5 group. The NC group served as a control group without any treatment, while the MD group received only TNF-α without additional treatment. The other 5 groups were pretreated for 6 hours in DMEM medium containing different concentrations of Poria cocos extract (concentrations are shown in Table 3 below, calculated based on the final concentration of dried Poria cocos extract powder added to the medium). After pretreatment, the medium for the other 6 groups was replaced with differentiation medium containing 20 ng / mL TNF-α, while the NC group was replaced with regular differentiation medium. Treatment continued for 6 days to induce cell fatigue. After treatment, cell viability was assessed using the MTT assay, and ROS and MMP levels were measured using a cell energy metabolism analyzer.
[0084] Table 3
[0085] The experimental results are shown in Table 4 and Figures 7 to 9 below. As shown in Table 4 and Figures 7 to 9, the improvement effect was best when the concentration of Poria cocos extract was 0.2 mg / mL. Compared with the MD group, the increase in cell viability and MMP level was the most significant, and the decrease in ROS level was the most significant. Therefore, 0.2 mg / mL Poria cocos extract was combined with different concentrations of vitamin B (vitamin B1) to prepare a composition for subsequent experiments.
[0086] Table 4
[0087] Compared with the NC group, #P < 0.05, ##P < 0.01; compared with the MD group, *P < 0.05, **P < 0.01
[0088] Example 3: Testing the effect of different ratios of Poria cocos extract combined with vitamin B on improving the fatigue model of C2C12 cells.
[0089] As mentioned earlier, the total daily dose of vitamin B can range from 2.5 mg to 50 mg. This example observes the effect of combining 13.64 mg of Poria cocos extract with low-dose (10 mg) and high-dose (50 mg) vitamin B on improving cellular fatigue.
[0090] The experimental results of Example 2 showed that using 0.2 mg / mL of Poria cocos extract had the best effect on improving cellular fatigue. Therefore, in the cell experiments conducted in this example, the concentration of Poria cocos extract was set at 0.2 mg / mL, and the concentration of vitamin B was adjusted accordingly. Thus, the combined vitamin B concentrations were 0.1466 mg / mL (low dose) and 0.7331 mg / mL (high dose).
[0091] Following the procedure in Preparation Example 2 (2-2), C2C12 myoblasts were seeded in 96-well plates, with three wells per group, for a total of 7 groups: NC group, MD group, group 1, group 2, group 3, group 4, and group 5. The NC group served as a control group without any treatment, while the MD group received only TNF-α without additional treatment. The five groups other than NC and MD were pretreated for 6 hours in DMEM medium containing different concentrations of Poria cocos extract (concentrations are shown in Table 5 below, calculated based on the dry powder weights of Poria cocos extract and vitamin B). After pretreatment, the medium for the six groups other than NC was replaced with differentiation medium containing 20 ng / mL TNF-α, while the NC group was replaced with regular differentiation medium. Treatment continued for 6 days to induce cell fatigue. After treatment, cell viability was assessed using the MTT assay, and ROS and MMP levels were measured using a cell energy metabolism analyzer.
[0092] Table 5
[0093] The experimental results are shown in Table 6 and Figures 10 to 12 below. As shown in Table 6 and Figures 10 to 12, compared with the administration of Poria cocos extract alone (Group 5) or vitamin B alone (Groups 3 and 4), Group 1 (low-dose vitamin B) and Group 2 (high-dose vitamin B), which combined Poria cocos extract with vitamin B, showed better results in improving cell viability, increasing MMP levels, and decreasing ROS levels (compared to the MD group). Even the combination of Poria cocos extract and low-dose vitamin B was more effective than high-dose vitamin B alone. These experimental results demonstrate that, compared with vitamin B alone, the combination of Poria cocos extract and vitamin B can further enhance the efficacy of vitamin B, improve cellular fatigue, and improve mitochondrial health. In addition, compared with the use of Poria cocos extract alone, the combination of Poria cocos extract and vitamin B also has a better effect on improving cellular fatigue. The above experiments further demonstrate that when Poria cocos extract is used in combination with vitamin B, a low dose of vitamin B can achieve the same effect as a high dose of vitamin B, effectively avoiding the side effects of using high doses of vitamin B.
[0094] Table 6
[0095] Compared with group NC, #P < 0.05, ##P < 0.01; compared with group MD, *P < 0.05, **P < 0.01; compared with group 1, aP < 0.05, aaP < 0.01; compared with group 2, bP < 0.05, bbP < 0.01
[0096] Example 4: Testing the effects of different ratios of Poria cocos extract combined with vitamin B on mitochondrial function in a C2C12 cell fatigue model.
[0097] Example 3 above has demonstrated that, compared to using Poria cocos extract or vitamin B alone, the combined use of Poria cocos extract and vitamin B is more effective in improving cellular fatigue and enhancing mitochondrial health. Example 4 will further observe the degree of improvement in mitochondrial function by using Poria cocos extract and vitamin B in different proportions by measuring the oxygen consumption rate and extracellular acidification rate of C2C12 cells.
[0098] (4-1) Experiment on oxygen consumption rate
[0099] Following the steps in Preparation Example 2 (2-2), C2C12 myoblasts were seeded in 96-well plates, with three wells per group, for a total of 7 groups: NC group, MD group, group 1, group 2, group 3, group 4, and group 5. The components, proportions, and treatment methods of each group were the same as in Example 3. After treatment, the mitochondrial oxygen consumption rate was determined by measuring the change in dissolved oxygen content in the culture medium using an energy metabolism analyzer. The measurement process is shown in Figure 13. Initially, the basal oxygen consumption rate of each group was measured. At approximately 18 minutes after the start of measurement, the ATP synthase inhibitor oligomycin was added to the culture medium of each group. Then, at 40 minutes, the uncoupling agent FCCP was added to the culture medium of each group. Finally, at 60 minutes, rotenone and antimycin A were added to the culture medium of each group to completely block mitochondrial activity.
[0100] The aforementioned basal mitochondrial oxygen consumption rate includes the mitochondrial oxidative phosphorylation oxygen consumption rate and the proton leakage oxygen consumption rate. Oxidative phosphorylation oxygen consumption refers to the oxygen consumed by the mitochondria during ATP synthesis, reflecting the mitochondrial ATP synthesis capacity in this experiment. Proton leakage oxygen consumption refers to the process where, after mitochondria consume oxygen, protons (H+) are transported to the outside of the mitochondrial inner membrane, but these protons do not enter ATP synthase to participate in ATP synthesis. Instead, they directly pass through the mitochondrial inner membrane back into the mitochondrial matrix. This process is pure oxygen consumption without ATP production, reflecting whether the basic functions of the mitochondria are operating normally in this experiment. Therefore, the decrease in the mitochondrial oxygen consumption rate measured after adding oligomycin, which inhibits ATP synthesis in mitochondria, reflects the proton leakage oxygen consumption rate (basal oxygen consumption rate minus the mitochondrial oxidative phosphorylation oxygen consumption rate). Adding FCCP to C2C12 cells disrupts the mitochondrial membrane potential, inducing significant proton leakage and oxygen consumption. Therefore, the oxygen consumption measured after FCCP addition represents the maximum mitochondrial oxygen consumption rate generated entirely by proton leakage, reflecting the maximum mitochondrial respiratory capacity. The value obtained by subtracting the basal oxygen consumption rate from the maximum oxygen consumption rate is the reserve respiration oxygen consumption rate, which reflects the mitochondrial ability to produce additional energy to cope with stress, exercise, or acute metabolic demands under basal metabolic conditions.
[0101] The results of the oxygen consumption rate experiment are shown in Table 7 and Figures 14 to 18 below. As shown in Table 7 and Figures 14 to 18, the basal respiratory oxygen consumption rate, maximum respiratory oxygen consumption rate, proton leakage oxygen consumption rate, ATP production oxygen consumption rate, and reserve respiratory oxygen consumption rate of the MD group (TNF-α-induced cell fatigue model) were significantly lower than those of the NC group without TNF-α treatment. In addition, compared with the MD group, the basal respiratory oxygen consumption rate, maximum respiratory oxygen consumption rate, proton leakage oxygen consumption rate, ATP production oxygen consumption rate, and reserve respiratory oxygen consumption rate were all increased regardless of whether Poria cocos extract was administered alone (Group 1), vitamin B (Groups 3 and 4), or the combination of Poria cocos extract and vitamin B (Groups 1 and 2). However, the effect of the combination of Poria cocos extract and vitamin B was better, and even when Poria cocos extract was used in combination with low-dose vitamin B (Group 1), its effect was higher than that of high-dose vitamin B alone (Group 5).
[0102] The above experimental results demonstrate that the combined use of Poria cocos extract and vitamin B can produce better effects in improving mitochondrial function and thus cellular fatigue, and this improvement can be achieved even with the combined use of low doses of vitamin B.
[0103] Table 7
[0104] Compared with group NC, #P < 0.05, ##P < 0.01; compared with group MD, *P < 0.05, **P < 0.01; compared with group 1, aP < 0.05, aaP < 0.01; compared with group 2, bP < 0.05, bbP < 0.01
[0105] (4-2) Extracellular acidification rate experiment
[0106] Following the steps in (2-2) of Preparation Example 2, C2C12 myoblasts were seeded in 96-well plates, with three wells per group, for a total of 7 groups: NC group, MD group, group 1, group 2, group 3, group 4, and group 5. The components, proportions, and treatment methods of each group were the same as in Example 3. After treatment, the extracellular acidification rate of each group was measured using a cell energy metabolism analyzer, i.e., the rate at which acidic metabolites produced by the cells are released into the extracellular space. The energy metabolism analyzer measures the extracellular acidification rate by measuring the pH change of the culture medium in each group. The measurement process is shown in Figure 19. Initially, the baseline extracellular acidification rate of each group was measured. At approximately 18 minutes after the start of the measurement, glucose was added to the culture medium of each group to continue measuring the extracellular acidification rate during glycolysis. Then, at 38 minutes, oligomycin, an ATP synthase inhibitor, was added to measure the extracellular acidification rate during glycolysis. Finally, at 60 minutes, 2-deoxy-D-glucose (2-DG) was added to completely block glycolysis. The extracellular acidification rates measured thereafter were not derived from glycolysis.
[0107] The aforementioned basal extracellular acidification rate reflects the acid production level of cells before glycolysis. The extracellular acidification increase rate after glycolysis is calculated by subtracting the basal extracellular acidification rate from the extracellular acidification rate after glycolysis, reflecting the degree of basal glycolysis. After the addition of oligomycin, the pathway for cells to obtain energy through ATP synthesis via oxidative phosphorylation is blocked, and energy is obtained solely through glycolysis. Therefore, the extracellular acidification rate reflecting the maximum degree of glycolysis can be measured. The extracellular acidification rate under maximum glycolysis minus the basal extracellular acidification rate is the maximum glycolysis extracellular acidification increase rate, reflecting the maximum degree of glycolysis. The glycolysis reserve extracellular acidification increase rate is calculated by subtracting the glycolysis extracellular acidification increase rate from the maximum glycolysis extracellular acidification increase rate, reflecting the maximum potential for glycolysis in cells.
[0108] The results of the extracellular acidification rate experiment are shown in Table 8 and Figures 20 to 22 below. As shown in Table 8 and Figures 20 to 22, the MD group (a TNF-α-induced cell fatigue model) showed significantly higher rates of extracellular acidification during glycolysis and at maximum glycolysis than the NC group without TNF-α treatment. Furthermore, its reserve extracellular acidification rate during glycolysis was significantly lower than that of the NC group. This indicates that the mitochondrial function in the cell fatigue model is poor, requiring glycolysis to generate energy, which in turn leads to easy cell fatigue. Furthermore, compared to the MD group, the rate of increase in extracellular acidification due to glycolysis and the rate of increase in extracellular acidification due to maximal glycolysis were both reduced when Poria cocos extract alone (Group 5) or vitamin B alone (Groups 3 and 4) or when Poria cocos extract and vitamin B in combination (Groups 1 and 2). However, the reduction was greater when Poria cocos extract and vitamin B in combination (Groups 1 and 2). Moreover, the effect of Groups 1 and 2 in enhancing the cellular reserve of glycolysis was more significant than that of Groups 3 to 5.
[0109] The above experimental results demonstrate that the combined use of Poria cocos extract and vitamin B can produce better effects in improving cellular fatigue and enhancing glycolysis reserves, and this improvement can be achieved even with low doses of vitamin B.
[0110] Table 8
[0111] Compared with group NC, #P < 0.05, ##P < 0.01; compared with group MD, *P < 0.05, **P < 0.01; compared with group 1, aP < 0.05, aaP < 0.01; compared with group 2, bP < 0.05, bbP < 0.01
[0112] The above embodiments are merely illustrative of the effectiveness of the present invention and to illustrate its technical features, and are not intended to limit the scope of protection of the present invention. Any changes or arrangements that can be easily made by those skilled in the art without departing from the technical principles of the present invention are within the scope of the present invention. Therefore, the scope of protection of the present invention is as set forth in the appended claims.
Claims
1. A composition characterized in that, It includes Poria cocos extract and vitamin B, wherein the weight ratio of Poria cocos extract to vitamin B is Poria cocos extract: vitamin B = 1:0.1-5.
2. The composition of claim 1, wherein The weight ratio of the Poria cocos extract to the vitamin B is Poria cocos extract: vitamin B = 1:0.1-2.
3. The composition of claim 1, wherein This Poria cocos extract is a polar solvent extract of Poria cocos.
4. The composition of claim 1, wherein The vitamin B is selected from the following groups: vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B9, vitamin B12, and combinations thereof.
5. The composition of claim 4, wherein This vitamin B is vitamin B1.
6. The composition according to any one of claims 1 to 5, wherein The composition is a pharmaceutical composition, a food composition, a cosmetic composition, a skincare composition, or a feed composition.
7. The composition of claim 6, wherein The composition is a pharmaceutical composition or a food composition.
8. The composition of claim 7, wherein The composition is taken such that the total daily dose of vitamin B is 2.5 mg to 50 mg.
9. The composition of claim 8, wherein, The composition is taken such that the total daily dose of vitamin B is 2.5 mg to 20 mg.
10. Use of the composition of any one of claims 1 to 9 for the preparation of a pharmaceutical composition. The pharmaceutical composition is used for at least one of the following: improving endurance performance, improving athletic ability, enhancing or restoring physical strength, promoting fatigue relief, preventing or improving myocardial weakness, improving cardiac function, maintaining normal energy metabolism, and maintaining or improving nervous system function.
